European Medicines Agency Confirms Positive Benefit-Risk Balance Of Topical Formulations Of Ketoprofen
Following a review of topical formulations of ketoprofen, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefit-risk balance of these medicines continues to be positive. However, the Committee recommended that doctors should inform patients on how to use these medicines appropriately. Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID). Topical formulations of ketoprofen are used to treat minor trauma, tendonitis, small-joint osteoarthritis, acute low-back pain and phlebitis.
Read the full story here
-
Topaz Pharmaceuticals Announces Positive Data From Topical Ivermectin Trials
Azzalure approved by Spanish Medicines and Healthcare Products Agency
Xenon Pharmaceuticals Initiates A Phase 2 Clinical Trial In Post Herpetic Neuralgia (PHN) For Topical XEN402
European CHMP Concludes Re-examination Of Ceftobiprole
Lytix Biopharma AS Announces Approval By Hungarian Authorities To Start Phase IIa Clinical Trial With LytixarTM In Gram Positive Skin Infections
